Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Yost

Showing results (91-100 of 140) with videos related to

Pageof 14
Sort By:
Science (New York, N.Y.)|July 24, 2025
High-resolution spatial mapping of cell state and lineage dynamics in vivo with PEtracerLuke W Koblan, Kathryn E Yost, Pu Zheng, et al.
Pleura and Peritoneum|March 23, 2026
Multicenter dose de-escalation phase I trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin in combination with systemic nab-paclitaxel in recurrent ovarian cancer patients: trial in progressVinita Popat, Paul H Frankel, Nora H Ruel, et al.
Nature Immunology|July 15, 2020
Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigenSantosha A Vardhana, Madeline A Hwee, Mirela Berisa, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
High-resolution spatial mapping of cell state and lineage dynamics <i>in vivo</i> with PEtracerLuke W Koblan, Kathryn E Yost, Pu Zheng, et al.
Cancers|September 9, 2022
Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast CancerXuan Ge, Susan E Yost, Jin Sun Lee, et al.
Breast Cancer Research : BCR|November 10, 2019
Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancerJin Sun Lee, Susan E Yost, Suzette Blanchard, et al.
NPJ Precision Oncology|December 14, 2025
Divergent oncogenic signaling and immune microenvironment changes in low-grade serous ovarian cancer patients undergoing intraperitoneal chemotherapyIsaac Bishara, Patrick A Cosgrove, Sumana Majumdar, et al.
Future Science OA|January 13, 2021
Co-stimulatory and co-inhibitory immune markers in solid tumors with <i>MET</i> alterationsKaren L Reckamp, Jasmine A McQuerry, Isa Mambetsariev, et al.
Journal of the American Academy of Dermatology|August 27, 2018
Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept studyAnne Lynn S Chang, Duy C Tran, John G D Cannon, et al.
Cancer Immunology, Immunotherapy : CII|June 9, 2023
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancerColt A Egelston, Weihua Guo, Susan E Yost, et al.
Pageof 14

Showing results (91-100 of 140) with videos related to

Sort By:
Pageof 14
Science (New York, N.Y.)|July 24, 2025
High-resolution spatial mapping of cell state and lineage dynamics in vivo with PEtracerLuke W Koblan, Kathryn E Yost, Pu Zheng, et al.
Pleura and Peritoneum|March 23, 2026
Multicenter dose de-escalation phase I trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin in combination with systemic nab-paclitaxel in recurrent ovarian cancer patients: trial in progressVinita Popat, Paul H Frankel, Nora H Ruel, et al.
Nature Immunology|July 15, 2020
Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigenSantosha A Vardhana, Madeline A Hwee, Mirela Berisa, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
High-resolution spatial mapping of cell state and lineage dynamics <i>in vivo</i> with PEtracerLuke W Koblan, Kathryn E Yost, Pu Zheng, et al.
Cancers|September 9, 2022
Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast CancerXuan Ge, Susan E Yost, Jin Sun Lee, et al.
Breast Cancer Research : BCR|November 10, 2019
Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancerJin Sun Lee, Susan E Yost, Suzette Blanchard, et al.
NPJ Precision Oncology|December 14, 2025
Divergent oncogenic signaling and immune microenvironment changes in low-grade serous ovarian cancer patients undergoing intraperitoneal chemotherapyIsaac Bishara, Patrick A Cosgrove, Sumana Majumdar, et al.
Future Science OA|January 13, 2021
Co-stimulatory and co-inhibitory immune markers in solid tumors with <i>MET</i> alterationsKaren L Reckamp, Jasmine A McQuerry, Isa Mambetsariev, et al.
Journal of the American Academy of Dermatology|August 27, 2018
Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept studyAnne Lynn S Chang, Duy C Tran, John G D Cannon, et al.
Cancer Immunology, Immunotherapy : CII|June 9, 2023
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancerColt A Egelston, Weihua Guo, Susan E Yost, et al.
Pageof 14